Payment overview · 2025
General Payments
$202.39
10 reported records · 9 companies
Healthcare provider profile · identity verified
Andreas Ward, ARNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · TALLAHASSEE, FL · NPI 1891064176
Verified facts
What the public records show
CMS Open Payments records show Andreas Ward, ARNP-BC received $202.39 in general payments during 2025 across 10 reported records.
Phathom Pharmaceuticals, Inc. accounted for 18.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.43 | 18.5% | 2 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $32.49 | 16.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.41 | 13.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.77 | 11.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.83 | 10.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.82 | 8.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.32 | 7.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $14.69 | 7.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.63 | 6.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $202.39 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $37.43 | 2 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $32.49 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.77 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.32 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
65 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 299 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 265 | 72 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 200 | 56 |
| Losartan Potassium | Losartan Potassium | 191 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 165 | 42 |
| Januvia | Sitagliptin Phosphate | 143 | 23 |
| Atorvastatin Calcium | Atorvastatin Calcium | 133 | 39 |
| Lacosamide | Lacosamide | 124 | 15 |
| Mounjaro | Tirzepatide | 122 | 18 |
| Potassium Chloride | Potassium Chloride | 121 | 37 |
| Gabapentin | Gabapentin | 117 | 45 |
| Metformin Hcl | Metformin Hcl | 108 | 29 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 107 | 95 |
| Simvastatin | Simvastatin | 105 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 27 |
| Tramadol Hcl | Tramadol Hcl | 102 | 31 |
| Allopurinol | Allopurinol | 94 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 92 | 27 |
| Pregabalin | Pregabalin | 83 | 20 |
| Lisinopril | Lisinopril | 81 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 34 |
| Mirtazapine | Mirtazapine | 70 | 19 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 67 | 32 |
| Eliquis | Apixaban | 65 | 25 |
| Jardiance | Empagliflozin | 61 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 14 |
| Carvedilol | Carvedilol | 60 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 19 |
| Alprazolam | Alprazolam | 56 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 56 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 14 |
| Entresto | Sacubitril/Valsartan | 52 | suppressed |
| Clonazepam | Clonazepam | 50 | suppressed |
| Ramipril | Ramipril | 50 | suppressed |
| Ezetimibe | Ezetimibe | 48 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 20 |
| Farxiga | Dapagliflozin Propanediol | 47 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Azithromycin | Azithromycin | 46 | 43 |
| Amoxicillin | Amoxicillin | 44 | 34 |
| Levofloxacin | Levofloxacin | 44 | 41 |
| Megestrol Acetate | Megestrol Acetate | 44 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 13 |
| Divalproex Sodium | Divalproex Sodium | 40 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 40 | 11 |
| Ibuprofen | Ibuprofen | 40 | 22 |
| Omeprazole | Omeprazole | 39 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 35 |
| Trazodone Hcl | Trazodone Hcl | 39 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 38 | suppressed |
| Lorazepam | Lorazepam | 37 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 37 | 12 |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Lactulose | Lactulose | 35 | 14 |
| Meloxicam | Meloxicam | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Fluconazole | Fluconazole | 33 | 25 |
| Latanoprost | Latanoprost | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | 12 |
| Colchicine | Colchicine | 31 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 12 |
| Valsartan | Valsartan | 31 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 29 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 27 |
| Erythromycin | Erythromycin Base | 26 | suppressed |
| Famotidine | Famotidine | 26 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 26 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 24 | 12 |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 17 |
| Ofloxacin | Ofloxacin | 24 | 22 |
| Oxycodone Hcl | Oxycodone Hcl | 24 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 23 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Phenytoin | Phenytoin | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 21 | 12 |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Scopolamine | Scopolamine | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 19 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 16 |
| Finasteride | Finasteride | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 16 | 15 |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 14 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Glipizide | Glipizide | 12 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Buprenorphine | Buprenorphine | 11 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $202.39 · 10 records | Phathom Pharmaceuticals, Inc. | ABRYSVO, AIRSUPRA, CAPLYTA, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, Nayzilam, OTEZLA, PREVNAR 20, REPATHA, VOQUEZNA, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error